On Friday 06/27/2025 the closing price of the ProQR Therapeutics B.V. share was $2.16 on BTT.
Compared to the opening price on Friday 06/27/2025 on BTT of $2.19, this is a drop of 1.62%.
ProQR Therapeutics B.V.'s market capitalization is $171.77 M by 105.21 M shares outstanding.
Is ProQR Therapeutics B.V. stock a Buy, Sell or Hold?
ProQR Therapeutics B.V. stock has received a consensus rating of buy. The average rating score is and is based on 14 buy ratings, 2 hold ratings, and 0 sell ratings.
What was the 52-week low for ProQR Therapeutics B.V. stock?
The low in the last 52 weeks of ProQR Therapeutics B.V. stock was 1.08. According to the current price, ProQR Therapeutics B.V. is 188.89% away from the 52-week low.
What was the 52-week high for ProQR Therapeutics B.V. stock?
The high in the last 52 weeks of ProQR Therapeutics B.V. stock was 4.70. According to the current price, ProQR Therapeutics B.V. is 43.40% away from the 52-week high.
What are analysts forecasts for ProQR Therapeutics B.V. stock?
The 16 analysts offering price forecasts for ProQR Therapeutics B.V. have a median target of 4.86, with a high estimate of 12.00 and a low estimate of 1.80. The median estimate represents a 41.95 difference from the last price of 2.04.
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
ProQR Therapeutics B.V. Analyst Opinions
All
Buy
Hold
Sell
Date
Analyst
Rating
Price
06/27/25
Cantor Fitzgerald
Maintained Buy
$8
gut
06/27/25
JMP Securities LLC
Maintained Buy
$8
gut
05/13/25
Oppenheimer & Co. Inc.
Maintained Buy
$9
gut
04/29/25
Evercore
Maintained Buy
$5
gut
03/14/25
Chardan Capital Markets
Maintained Buy
$4
gut
03/14/25
H.C. Wainwright & Co.
Maintained Buy
$12
gut
05/10/24
Chardan Capital Markets
Maintained Buy
$2.5
gut
05/10/24
H.C. Wainwright & Co.
Maintained Buy
$5
gut
04/18/24
Citigroup Corp.
Maintained Hold
$2
neutral
03/14/24
H.C. Wainwright & Co.
Maintained Buy
$5
gut
03/14/24
Chardan Capital Markets
Maintained Buy
$2.5
gut
11/08/23
Raymond James Financial, Inc.
Maintained Buy
$4
gut
11/08/23
Chardan Capital Markets
Upgraded to Buy
$2
gut
09/18/23
Citigroup Corp.
Maintained Buy
$1.79999995231628
gut
08/07/23
H.C. Wainwright & Co.
Maintained Buy
$5
gut
08/04/23
Chardan Capital Markets
Maintained Hold
$2
neutral
ProQR Therapeutics B.V. Estimates* in EUR
2025
2026
2027
2028
2029
Revenue
22
15
24
71
129
Dividend
0.00
0.00
0.00
0.00
0.00
Dividend Yield (in %)
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
EPS
-0.37
-0.48
-0.47
-0.22
0.15
P/E Ratio
-4.75
-3.66
-3.72
-8.00
11.67
EBIT
-42
-50
-68
-35
22
EBITDA
7
-43
-16
-15
15
Net Profit
-36
-48
-56
-29
16
Net Profit Adjusted
-
-
-
-
-
Pre-Tax Profit
-37
-48
-65
-31
26
Pre-Tax Profit Reported
-
-
-
-
-
EPS (Non-GAAP) ex. SOE
-
-
-
-
-
EPS (GAAP)
-0.30
-0.44
-0.56
-0.16
0.35
Gross Income
14
19
18
46
150
Cash Flow from Investing
-1
-1
-3
-11
-7
Cash Flow from Operations
-48
-58
-77
-21
-33
Cash Flow from Financing
-1
-
165
165
186
Cash Flow per Share
-
-
-
-
-
Free Cash Flow
-
-
-
-
-
Free Cash Flow per Share
-
-
-
-
-
Book Value per Share
-
-
-
-
-
Net Debt
-
-
-
-
-
Research & Development Exp.
47
50
56
63
71
Capital Expenditure
1
1
3
10
7
Selling, General & Admin. Exp.
14
16
24
27
30
Shareholder’s Equity
107
77
182
215
253
Total Assets
195
155
297
344
395
Previous Quarter ending 03/31/25
Current Quarter ending 06/30/25
Next Quarter ending 09/30/25
Current Year ending 12/31/25
Next Year ending 12/31/26
Earnings Estimates
No. of Analysts
-
7
7
8
8
Average Estimate
-
-0.079 EUR
-0.095 EUR
-0.368 EUR
-0.478 EUR
Year Ago
-
-0.036 EUR
-0.109 EUR
-0.349 EUR
-
Publish Date
-
7/31/2025
11/5/2025
-
-
Revenue Estimates
No. of Analysts
-
6
6
9
7
Average Estimate
-
5 EUR
5 EUR
22 EUR
15 EUR
Year Ago
-
7 EUR
4 EUR
20 EUR
-
Publish Date
-
7/31/2025
11/5/2025
-
-
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
2024
2023
2022
2021
2020
2019
2018
Sales
20.45
7.04
4.24
1.60
0.00
0.00
0.00
Change of sales in %
190.38
65.99
165.11
-
-
-
-
Gross profit on sales
17.46
-
1.59
-
-2.68
-2.30
-1.12
Gross profit on sales change in %
-
-
-
-
-16.89
-104.28
6.49
Operating income
-33.65
-37.70
-68.82
-68.83
-59.07
-66.46
-49.61
Operating income change in %
10.73
45.22
0.02
-16.52
11.11
-33.95
-4.75
Income before tax
-30.24
-30.07
-68.09
-72.51
-52.63
-63.85
-43.75
Income before tax change in %
-0.58
55.84
6.10
-37.77
17.57
-45.93
11.18
Income after tax
-30.03
-30.40
-68.43
-72.83
-53.08
-63.22
-43.53
Income after tax change in %
1.21
55.58
6.05
-37.21
16.03
-45.24
11.57
Balance Sheet in Mio. USD
2024
2023
2022
2021
2020
2019
2018
Total liabilities
82.22
106.59
113.35
109.57
51.61
26.61
20.06
Long-term liabilities per share
0.41
0.88
1.17
1.15
0.78
0.29
0.25
Equity
91.70
45.72
69.49
128.76
69.19
105.33
105.95
Equity change in %
100.57
-34.59
-46.00
85.32
-34.03
-0.31
124.71
Balance sheet total
173.92
152.31
182.84
238.33
120.80
131.93
126.01
Balance sheet total change in %
14.19
-16.70
-23.28
97.30
-8.44
4.70
97.61
Key Data in USD
2024
2023
2022
2021
2020
2019
2018
Sales per share
0.24
0.09
0.06
0.02
0.00
0.00
0.00
P/E ratio (year end quote, basic EPS)
-
-
-
-
-
-
-
P/E ratio (year end quote, diluted EPS)
-
-
-
-
-
-
-
Dividend yield in %
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Equity ratio in %
52.73
30.02
38.01
54.03
57.27
79.83
84.08
Debt ratio in %
47.27
69.98
61.99
45.97
42.73
20.17
15.92
ProQR Therapeutics B.V. Dividend Calendar
Date
Name
Dividend
*yield
Currency
2024
ProQR Therapeutics B.V.
0.00
0.00
USD
2023
ProQR Therapeutics B.V.
0.00
0.00
USD
2022
ProQR Therapeutics B.V.
0.00
0.00
USD
2021
ProQR Therapeutics B.V.
0.00
0.00
USD
2020
ProQR Therapeutics B.V.
0.00
0.00
USD
2019
ProQR Therapeutics B.V.
0.00
0.00
USD
2018
ProQR Therapeutics B.V.
0.00
0.00
USD
2017
ProQR Therapeutics B.V.
0.00
0.00
USD
2016
ProQR Therapeutics B.V.
0.00
0.00
USD
2015
ProQR Therapeutics B.V.
0.00
0.00
USD
2014
ProQR Therapeutics B.V.
0.00
0.00
USD
2013
ProQR Therapeutics B.V.
-
-
USD
2012
ProQR Therapeutics B.V.
-
-
USD
*Yield of the Respective Date
ProQR Therapeutics B.V. Calendar
Event
Estimate
Info
Date
Earnings Report
-0.079 EUR
Q2 2025 Earnings Release
07/31/2025
Earnings Report
-0.095 EUR
Q3 2025 Earnings Release
11/05/2025
Earnings Report
-0.093 EUR
Q4 2025 Earnings Release
02/19/2026
Earnings Report
-0.119 EUR
Q1 2026 Earnings Release
05/07/2026
ProQR Therapeutics B.V. Past Events
Event
Actual EPS
Info
Date
Annual General Meeting
-0.346 USD
Annual General Meeting
06/03/2025
Earnings Report
-0.105 USD
Q1 2025 Earnings Release
05/08/2025
Earnings Report
-0.096 USD
Q4 2024 Earnings Release
03/13/2025
Earnings Report
-0.110 USD
Q3 2024 Earnings Release
11/07/2024
Earnings Report
-0.032 USD
Q2 2024 Earnings Release
08/08/2024
Annual General Meeting
-0.378 USD
Annual General Meeting
05/22/2024
Earnings Report
-0.098 USD
Q1 2024 Earnings Release
05/09/2024
Earnings Report
-0.075 USD
Q4 2023 Earnings Release
03/13/2024
Earnings Report
-0.076 USD
Q3 2023 Earnings Release
11/07/2023
Earnings Report
-0.109 USD
Q2 2023 Earnings Release
08/03/2023
Annual General Meeting
-0.956 USD
Annual General Meeting
05/17/2023
Earnings Report
-0.118 USD
Q1 2023 Earnings Release
05/16/2023
Earnings Report
-0.163 USD
Q4 2022 Earnings Release
03/29/2023
Earnings Report
-0.342 USD
Q3 2022 Earnings Release
11/09/2022
Earnings Report
-0.224 USD
Q2 2022 Earnings Release
08/04/2022
Annual General Meeting
-1.135 USD
Annual General Meeting
06/30/2022
Earnings Report
-0.224 USD
Q1 2022 Earnings Release
05/05/2022
Earnings Report
-0.297 USD
Q4 2021 Earnings Release
02/24/2022
ProQR Therapeutics B.V. Profile
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.
Moody’s Daily Credit Risk Score
Risk
Low
Medium
High
9
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s
balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit
risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into
account day-to-day movements in market value compared to a company’s liability structure.
